demonstrated that exosomes carrying CRISPR/Cas9 plasmid DNA may specifically target pancreatic cancer cells with mutant KRAS G12D, leading to the deletion of target genes and the subsequent inhibition of tumor growth. This evidence concerns the gene KRAS and familial pancreatic carcinoma.